Genitope Corporation to Adjourn Special Meeting of Stockholders to March 14, 2008

FREMONT, Calif.--(Business Wire)--
Genitope Corporation (NASDAQ:GTOP) today announced that it intends
to adjourn its special meeting of stockholders scheduled to be held on
Tuesday, March 11, 2008 and reconvene the meeting on Friday, March 14
at 10:00 am PT at 6900 Dumbarton Circle, Fremont, CA 94555. The
purpose of the meeting is to obtain stockholder approval of an
amendment to Genitope's Amended and Restated Certificate of
Incorporation to increase the total number of shares of common stock
that Genitope is authorized to issue from 65 million to 125 million
shares.

About Genitope Corporation

Genitope Corporation (Fremont, Calif.) is a biotechnology company
focused on the research and development of novel immunotherapies for
the treatment of cancer. Genitope Corporation's lead product
candidate, MyVax(R) personalized immunotherapy, is a patient-specific
active immunotherapy based on the unique genetic makeup of a patient's
tumor and is designed to activate the patient's immune system to
identify and attack cancer cells. Genitope is also developing a
monoclonal antibody panel that it believes will potentially represent
a novel, personalized approach for treating NHL. For more information
about Genitope, please log on to www.genitope.com.

Genitope Corporation
Investor Contact:
John Vuko, Chief Financial Officer, 510-284-3000
IR@genitope.com
or
Edelman
Media Contact:
Marites Cristobal, 323.202.1424
Cell: 415.819.2214
marites.cristobal@edelman.com

Copyright Business Wire 2008